InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Explore the detailed record of transactions filed by TRENARY C RUSSELL III, Chairman & CEO. Officer active across 1 companies, notably Outlook Therapeutics, Inc.. In total, 5 filings have been recorded. Total volume traded: €106k. The latest transaction was filed on 21 June 2022 — Acquisition. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations5 total
€20,05219,925 shares@ €1.00640.073% mcap18.9% of flow
Common Stock
SEC:0001209191-22-038985:0·
Ideal exit: 18 Mar 2023 (T+270)
€30,73925,000 shares@ €1.22960.11% mcap71.3% of flow
Common Stock
SEC:0001209191-21-068137·
Ideal exit: 2 Sept 2022 (T+270)
€30,73925,000 shares@ €1.22960.11% mcap28.9% of flow
Common Stock
SEC:0001209191-21-068137:0·
Ideal exit: 2 Sept 2022 (T+270)
€12,36810,000 shares@ €1.23680.045% mcap28.7% of flow
Common Stock
SEC:0001209191-21-067644·
Ideal exit: 29 Aug 2022 (T+270)
€12,36810,000 shares@ €1.23680.045% mcap11.6% of flow
Common Stock
SEC:0001209191-21-067644:0·
Ideal exit: 29 Aug 2022 (T+270)
5 of 5 declarations
About TRENARY C RUSSELL III
C. Russell Trenary III is the Chief Executive Officer of Outlook Therapeutics, Inc. He leads the company with a strategic vision, focusing on innovation and growth. His leadership is crucial in guiding the company's initiatives in the biotechnology sector.
